Evolus, Inc. (NASDAQ:EOLS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $16.00.

EOLS has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday. Stifel Nicolaus dropped their target price on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. BTIG Research restated a “buy” rating and set a $13.00 price objective on shares of Evolus in a research report on Wednesday. Finally, Mizuho set a $15.00 price objective on shares of Evolus in a report on Wednesday, February 4th.

Evolus Stock Down 2.3%

Evolus stock opened at $5.53 on Monday. The stock has a market cap of $359.78 million, a price-to-earnings ratio of -6.83 and a beta of 1.02. The business has a 50-day simple moving average of $5.04 and a 200 day simple moving average of $6.23. Evolus has a 52 week low of $4.09 and a 52 week high of $13.81.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to analysts’ expectations of $89.58 million. On average, research analysts anticipate that Evolus will post -0.61 earnings per share for the current year.

Insiders Place Their Bets

In other Evolus news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the sale, the insider owned 354,388 shares in the company, valued at $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Evolus

Several institutional investors have recently modified their holdings of the company. Manchester Capital Management LLC purchased a new position in shares of Evolus during the 2nd quarter valued at about $26,000. State of Alaska Department of Revenue purchased a new stake in Evolus in the third quarter worth approximately $26,000. Larson Financial Group LLC boosted its stake in Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after buying an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Evolus during the fourth quarter valued at approximately $34,000. Finally, Wexford Capital LP purchased a new position in shares of Evolus during the third quarter worth approximately $37,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.